PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular... (

HOME >> MEDICINE >> TECHNOLOGY

PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy

Date:10/11/2007

- Data Presented at 36th Child Neurology Society Annual Meeting -

SOUTH PLAINFIELD, N.J., Oct. 11 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced pharmacokinetic and safety data from a Phase 2 clinical trial of PTC124 in patients with Duchenne muscular dystrophy (DMD) due to a nonsense mutation. The results, which include data from the third and final cohort of the study, show that treatment with PTC124 appeared well tolerated at all three dose levels and target plasma concentrations were achieved at the mid- and high-dose levels. These data were presented today at the 36th Annual Meeting of the Child Neurology Society (CNS) in Quebec City, Canada.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

In the study, patients received 28 days of PTC124 treatment at one of three dose levels. All clinical trial participants are boys with a nonsense mutation in the dystrophin gene, substantially elevated serum creatine kinase levels, and symptoms associated with DMD. The analysis presented today showed that PTC124 appeared well tolerated among the 38 boys included in the study. Adverse events were infrequent, mild to moderate in severity, and did not result in therapy interruptions or discontinuations. There were no concerns based on physical examinations, vital sign measurements, electrocardiograms or laboratory parameters. Compliance with PTC124 treatment was excellent at all three dose levels. Target plasma concentrations associated with activity in a preclinical model of DMD were achieved at the mid- and high-dose levels.

"DMD is a disorder with a significant need for better treatment options and we are encouraged by the results we have seen to date with PTC124," said Brend
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

Post Your Comments:

(Date:12/3/2009)..., ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec...s today announced the signing of an agreement to p...sing SoftGenetics, NextGENe software for next-gene..., (Logo: http://www.newscom.com/cgi-bin/prnh/... Ambry,s CSO said, "Our team at Ambry has been pro...

(Date:12/3/2009)... , DOYLESTOWN, Pa., Dec. 3 /PRNewswire-FirstCa... Corporation, (Nasdaq: QGLY ) www.quigleyco.com ...s evaluation of its opportunities to develop presc...ncluded that it is in its best interests to focus ...ich may include but are not limited to its Cold-EE...

(Date:12/3/2009)..., WILMINGTON, Del., Dec. 3 Parag...rmaceutical risk management and optimal medication...9, on the FDA,s draft guidance on REMS - Risk Eval...ications for REMS lifecycle management. Dr. Gary ...expert on REMS and risk management programs, will ...

Breaking Medicine Technology:Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2 Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3 Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2 Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3 Photo 3A Stopain and the Arthritis Foundation Join Forces to Promote the Benefits of Staying Active 54192 1 Photo 3A Stopain and the Arthritis Foundation Join Forces to Promote the Benefits of Staying Active 54192 2 Prime Therapeutics 2009 Drug Trend Insights Shows Drug Spending Slows to Lowest Rate on Record 54189 1 Prime Therapeutics 2009 Drug Trend Insights Shows Drug Spending Slows to Lowest Rate on Record 54189 2 Prime Therapeutics 2009 Drug Trend Insights Shows Drug Spending Slows to Lowest Rate on Record 54189 3 Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets 54186 1 Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets 54186 2

[0] Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects [0] Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution [0] Webinar to Explore FDA Draft REMS Guidance and Its Implications for Lifecycle Management

...te phase III trial - , , SOUTH SAN FRANCISCO, Cal...nnounced top-line results from their phase II stud...ders. The data was presented on March 27th at the...ican College of Medical Genetics by Brendan Lee, M...igator and Professor Department of Molecular and H...

... in combination with the most commonly used doses ...tients with mixed dyslipidemia , , ORLANDO, Fla.,...tt ,s TRILIPIX(R) (fenofibric acid) delayed-releas...m met all of the study,s primary endpoints. TRILI...m 5 mg significantly improved HDL cholesterol and ...

Other Medicine Technology:Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 2 Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 3 Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 4 New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2 New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3 New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4 New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5

Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management

(Date:12/3/2009)...rn causes demand for affordable drug and alcohol r... sharp increase in demand for its services and att... led to an increase in alcoholic binge drinking, d... (PRWEB) December 3, 2009 -- Mountainside ...spike in demand for its services due to the econom...

(Date:12/3/2009)... of screening test, researcher says, , ...rch points to the possibility of a genetic link be...h high blood pressure who had a gene variant that ...d to be twice as likely as those without the varia...nd. , The finding may lead to a way to identify...

(Date:12/3/2009)...ewswire-USNewswire/ -- The American Association fo...rom one of the largest studies to date on passive ...e Northern California Cancer Center (NCCC) . ,...d cigarettes and who were exposed to secondhand ci...dulthood--had a significantly increased breast can...

(Date:12/3/2009)...PRNewswire-USNewswire/ -- The Board of Trustees of...mously voted to elect three new members during its... is co-founder and Managing Director of De Novo Ve...650 million from three funds in early stage medica...ded Medicus Venture Partners in 1989. He has inves...

(Date:12/3/2009)... For California,s 3.4 million owne...remains one of the most significant threats to not...o their business,s viability. ,, "As the reces...ners of small businesses are recognizing the need ...ed disability coverage," said Michael Hagedorn, ...

Breaking Medicine News(10 mins):Health News:Economic Crisis Causes Acute Demand for Affordable Drug Addiction Treatment 2 Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2 Health News:Northern California Cancer Center's Findings on Breast Cancer and Secondhand Smoke Released Internationally by the American Association for Cancer Research 2 Health News:Salk Institute Board of Trustees Elects Leaders in Venture Capital and Publishing to its Membership 2 Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 2 Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 3 Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 4

[0] Economic Crisis Causes Acute Demand for Affordable Drug Addiction Treatment [0] Vitamin D May Be Tied to Heart Disease Via Genes [2] Northern California Cancer Center's Findings on Breast Cancer and Secondhand Smoke Released Internationally by the American Association for Cancer Research [0] Salk Institute Board of Trustees Elects Leaders in Venture Capital and Publishing to its Membership [1] New Disability Income Insurance Options Provide More Choice for California's Small Business Owners

...ealth Status; Anthem Blue Cross and Blue, Shield p...more than 5,000, Kentuckians located in the easte...LLE, Ky., Nov. 14 Anthem Blue Cross and Blue,Shie...tate. Anthem has assembled a dedicated team to col...

...s first diagnosed in childhood , , WEDNESD...be 87 years old, but he still remembers the day ...1925. , "I went to the hospital at five years of a...aid Cleveland, of Syracuse, N.Y. , He didn,t die....

...f frustration from,those who live with the risk of...tudies suggest that the comprehensive and often co...ming diabetes patients to the point,of inaction. S...ss of incorporating a complete diabetes management...

...uarter Ended September 30, 2007 ...348 Average Patient Charge (APC) ... uncompensated care as a percent of gross revenue .../Metro,Corporation (Nasdaq: RURL ), a leading pro...

...rug development platform, SEATTLE, Nov. 14 Analy... the progress and prospects of three of Cell,Thera...IC) oncology drug,candidates, as well as informati...Strategies, New Opportunities",in New York on Frid...

...tal, the nation,s,largest and most experienced den...Award from Benefits Selling magazine as the dental... design and network availability. The,awards were ...rences in eight categories that are determined to,...

Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index A Full and Long Life, Despite Diabetes Natural Antioxidants Help Reduce Oxidative Stress in Diabetes Treatment Rural/Metro Announces Results for Fiscal 2008 First Quarter; Fiscal 2007 Fourth Quarter and Full Year Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline Brokers Name Delta Dental the Best in Coverage, Plan Design and Networks

...eye protection Properly manufactured radiation pr...f scatter radiation. Our high quality frames and m...h minimized weight. Our lenses are made of Schott ... standards. Most Pulse Glasses are offered with le...

...re designed with the safety and comfort of the pra...lso called SF-6) leaded glass, the industry standa...t standards, as set for optical clarity, visible l...While our eyewear is protecting your eyes, it also...

Glasses,metal,trifocal

Medicine Products:

Wrap Metal Standard Wrap Around Frame Glasses,metal,trifocal

PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular...( - Data Presented at 36th Child N...),Health